Benzinga's Top #PreMarket Losers

By: via Benzinga
Chimerix Inc (NASDAQ: CMRX) shares dipped 74.70 percent to $9.00 following Phase 3 trial failure. Chimerix announced in a press ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.